| 1 |
Cunningham KT, Mills KHG. Trained innate immunity in hematopoietic stem cell and solid organ transplantation[J]. Transplantation, 2021, 105(8)：1666-1676.
|
| 2 |
Mak ML, Reid KT, Crome SQ. Protective and pathogenic functions of innate lymphoid cells in transplantation[J]. Clin Exp Immunol, 2023, 213(1): 23-39.
|
| 3 |
Duneton C, Winterberg PD, Ford ML. Activation and regulation of alloreactive T cell immunity in solid organ transplantation[J]. Nat Rev Nephrol, 2022, 18(10)：663-676.
|
| 4 |
Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling[J]. Nat Rev Immunol, 2016, 16(7)：407-420.
|
| 5 |
Lu A, Magupalli VG, Ruan J, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes[J]. Cell, 2014, 156(6)：1193-1206.
|
| 6 |
Willingham SB, Allen IC, Bergstralh DT, et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways[J]. J Immunol, 2009, 183(3)：2008-2015.
|
| 7 |
Mangan MSJ, Olhava EJ, Roush WR, et al. Targeting the NLRP3 inflammasome in inflammatory diseases[J]. Nat Rev Drug Discov, 2018, 17(8)：588-606.
|
| 8 |
Liston A, Masters SL. Homeostasis-altering molecular processes as mechanisms of inflammasome activation[J]. Nat Rev Immunol, 2017, 17(3)：208-214.
|
| 9 |
Yu Y, Cheng Y, Pan Q, et al. Effect of the selective NLRP3 inflammasome inhibitor mcc950 on transplantation outcome in a pig liver transplantation model with organs from donors after circulatory death preserved by hypothermic machine perfusion[J]. Transplantation, 2019, 103(2): 353-362.
|
| 10 |
Xu KY, Tong S, Wu CY, et al. Nlrp3 inflammasome inhibitor MCC950 ameliorates obliterative bronchiolitis by inhibiting Th1/Th17 response and promoting treg response after orthotopic tracheal transplantation in mice[J]. Transplantation, 2020, 104(6): e151-e163.
|
| 11 |
Afonina IS, Zhong Z, Karin M, et al. Limiting inflammation-the negative regulation of NF-kappaB and the NLRP3 inflammasome[J]. Nat Immunol, 2017, 18(8)：861-869.
|
| 12 |
Alyaseer AAA, de Lima MHS, Braga TT. The role of NLRP3 inflammasome activation in the epithelial to mesenchymal transition process during the fibrosis[J]. Front Immunol, 2020, 11：883.
|
| 13 |
Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11[J]. Nature, 2011, 479(7371)：117-121.
|
| 14 |
Ding J, Wang K, Liu W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family[J]. Nature, 2016, 535(7610)：111-116.
|
| 15 |
Komada T, Muruve DA. The role of inflammasomes in kidney disease[J]. Nat Rev Nephrol, 2019, 15(8)：501-520.
|
| 16 |
Gaidt MM, Ebert TS, Chauhan D, et al. Human monocytes engage an alternative inflammasome pathway[J]. Immunity, 2016, 44(4): 833-846.
|
| 17 |
Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors[J]. Cell Death Dis, 2019, 10(2)：128.
|
| 18 |
Rühl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(＋) efflux[J]. Eur J Immunol, 2015, 45(10)：2927-2936.
|
| 19 |
Muñoz-Planillo R, Kuffa P, Martínez-Colón G, et al. K(＋) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter[J]. Immunity, 2013, 38(6)：1142-1153.
|
| 20 |
Tang T, Lang X, Xu C, et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation[J]. Nat Commun, 2017, 8(1)：202.
|
| 21 |
Campden RI, Zhang Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation[J]. Arch Biochem Biophys, 2019, 670：32-42.
|
| 22 |
Zhong Z, Liang S, Sanchez-Lopez E, et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation[J]. Nature, 2018, 560(7717)：198-203.
|
| 23 |
Zhou R, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation[J]. Nature, 2011, 469(7329)：221-225.
|
| 24 |
Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM, et al. Inflammation in renal diseases: new and old players[J]. Front Pharmacol, 2019, 10：1192.
|
| 25 |
Turner CM, Arulkumaran N, Singer M, et al. Is the inflammasome a potential therapeutic target in renal disease？[J]. BMC Nephrol, 2014, 15：21.
|
| 26 |
Toki Y, Takenouchi T, Harada H, et al. Extracellular ATP induces P2X7 receptor activation in mouse Kupffer cells, leading to release of IL-1beta, HMGB1, and PGE2, decreased MHC class I expression and necrotic cell death[J]. Biochem Biophys Res Commun, 2015, 458(4)：771-776.
|
| 27 |
Minutoli L, Puzzolo D, Rinaldi M, et al. ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury[J]. Oxid Med Cell Longev, 2016: 2183026.
|
| 28 |
Mauerhofer C, Grumet L, Schemmer P, et al. Combating ischemia-reperfusion injury with micronutrients and natural compounds during solid organ transplantation: data of clinical trials and lessons of preclinical findings[J]. Int J Mol Sci, 2021, 22(19): 10675.
|
| 29 |
Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms[J]. Cell Discov, 2020, 6：36.
|
| 30 |
Furuichi K, Wada T, Iwata Y, et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury[J]. Crit Care Med, 2006, 34(9): 2447-2455.
|
| 31 |
Su Y, Wang Y, Liu M, et al. Hydrogen sulfide attenuates renal I/R-induced activation of the inflammatory response and apoptosis via regulating Nrf2-mediated NLRP3 signaling pathway inhibition[J]. Mol Med Rep, 2021, 24(1)：518.
|
| 32 |
Jiménez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, et al. Inflammasome-mediated inflammation in liver ischemia-reperfusion injury[J]. Cells, 2019, 8(10): 1131.
|
| 33 |
Kan C, Ungelenk L, Lupp A, et al. Ischemia-reperfusion injury in aged livers-the energy metabolism, inflammatory response, and autophagy[J]. Transplantation, 2018, 102(3)：368-377.
|
| 34 |
Zhong W, Rao Z, Rao J, et al. Aging aggravated liver ischemia and reperfusion injury by promoting STING-mediated NLRP3 activation in macrophages[J]. Aging Cell, 2020, 19(8)：e13186.
|
| 35 |
Li N, Zhou H, Wu H, et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3[J]. Redox Biol, 2019, 24: 101215.
|
| 36 |
Ronca V, Wootton G, Milani C, et al. The immunological basis of liver allograft rejection[J]. Front Immunol, 2020, 11：2155.
|
| 37 |
Dessing MC, Kers J, Damman J, et al. Donor and recipient genetic variants in NLRP3 associate with early acute rejection following kidney transplantation[J]. Sci Rep, 2016, 6：36315.
|
| 38 |
Wanderer AA. Rationale and timeliness for IL-1beta-targeted therapy to reduce allogeneic organ injury at procurement and to diminish risk of rejection after transplantation[J]. Clin Transplant, 2010, 24(3)：307-311.
|
| 39 |
Hong BJ, Liu H, Wang ZH, et al. Inflammasome activation involved in early inflammation reaction after liver transplantation[J]. Immunol Lett, 2017, 190：265-271.
|
| 40 |
Amores-Iniesta J, Barberà-Cremades M, Martínez CM, et al. Extracellular ATP activates the NLRP3 inflammasome and is an early danger signal of skin allograft rejection[J]. Cell Rep, 2017, 21(12)：3414-3426.
|
| 41 |
Wei C, Ma L, Chi H, et al. The NLRP3 inflammasome regulates corneal allograft rejection through enhanced phosphorylation of STAT3[J]. Am J Transplant, 2020, 20(12)：3354-3366.
|
| 42 |
Yoshino O, Wong BKL, Cox DRA, et al. Elevated levels of circulating mitochondrial DNA predict early allograft dysfunction in patients following liver transplantation[J]. J Gastroenterol Hepatol, 2021, 36(12)：3500-3507.
|
| 43 |
Lee DD, Croome KP, Shalev JA, et al. Early allograft dysfunction after liver transplantation: an intermediate outcome measure for targeted improvements[J]. Ann Hepatol, 2016, 15(1)：53-60.
|
| 44 |
Costa TJ, Potje SR, Fraga-Silva TFC, et al. Mitochondrial DNA and TLR9 activation contribute to SARS-CoV-2-induced endothelial cell damage[J]. Vascul Pharmacol, 2022, 142：106946.
|
| 45 |
Shen J, Dai Z, Li Y, et al. TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy[J]. Diabetol Metab Syndr, 2022, 14(1)：26.
|
| 46 |
Martínez-García JJ, Martínez-Banaclocha H, Angosto-Bazarra D, et al. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis[J]. Nat Commun, 2019, 10(1): 2711.
|
| 47 |
Hu X, Zhang H, Zhang Q, et al. Emerging role of STING signalling in CNS injury: inflammation, autophagy, necroptosis, ferroptosis and pyroptosis[J]. J Neuroinflammation, 2022, 19(1)：242.
|
| 48 |
Gaidt MM, Ebert TS, Chauhan D, et al. The DNA inflammasome in human myeloid cells is initiated by a STING-cell death program upstream of NLRP3[J]. Cell, 2017, 171(5)：1110-1124.e18.
|
| 49 |
Coll RC. Role reversal: adaptive immunity instructs inflammasome activation for anti-viral defence[J]. EMBO J, 2019, 38(21)：e103533.
|
| 50 |
Wang Q, Bu Q, Liu M, et al. XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression[J]. JHEP Rep, 2022, 4(11): 100555.
|
| 51 |
Kawashima M, Juvet SC. The role of innate immunity in the long-term outcome of lung transplantation[J]. Ann Transl Med, 2020, 8(6)：412.
|
| 52 |
Bernasconi E, Pattaroni C, Koutsokera A, et al. Airway microbiota determines innate cell inflammatory or tissue remodeling profiles in lung transplantation[J]. Am J Respir Crit Care Med, 2016, 194(10): 1252-1263.
|
| 53 |
Gugliandolo E, Fusco R, Ginestra G, et al. Involvement of TLR4 and PPAR-alpha receptors in host response and NLRP3 inflammasome activation, against pulmonary infection with pseudomonas aeruginosa[J]. Shock, 2019, 51(2)：221-227.
|
| 54 |
D′Amico R, Fusco R, Cordaro M, et al., Modulation of NLRP3 inflammasome through formyl peptide receptor 1 (Fpr-1) pathway as a new therapeutic target in bronchiolitis obliterans syndrome[J]. Int J Mol Sci, 2020, 21(6)：2144.
|